Christopher Bulow
Fondateur chez ResistanceBio, Inc.
Profil
Christopher Bulow founded Viosera Therapeutics Inc. in 2016, where he worked as Chief Operating Officer.
Dr. Bulow also founded resistanceBio, Inc., where he worked as Chief Financial Officer & Director.
Postes actifs de Christopher Bulow
| Sociétés | Poste | Début |
|---|---|---|
ResistanceBio, Inc.
 ResistanceBio, Inc. BiotechnologyHealth Technology ResistanceBio, Inc. is a company that focuses on overcoming treatment-resistant cancer. The company is based in San Carlos, CA. The company's mission is to defeat this type of cancer by developing a novel class of multi-targeted oncology treatments called Resistance Suppressing Therapy (REST). ResistanceBio was founded by Nicholas Goldner and Christopher Bulow, with Nicholas Goldner serving as the CEO since incorporation. | Fondateur | - |
Anciens postes connus de Christopher Bulow
| Sociétés | Poste | Fin |
|---|---|---|
Viosera Therapeutics Inc.
 Viosera Therapeutics Inc. Miscellaneous Commercial ServicesCommercial Services Viosera Therapeutics Inc. engages in the research and develop services that predict and block drug resistance in cancer and bacteria. The company was founded by Christopher Bulow and Nicholas Goldner and is headquartered in St. Louis, MO. | Fondateur | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Viosera Therapeutics Inc.
Viosera Therapeutics Inc. Miscellaneous Commercial ServicesCommercial Services Viosera Therapeutics Inc. engages in the research and develop services that predict and block drug resistance in cancer and bacteria. The company was founded by Christopher Bulow and Nicholas Goldner and is headquartered in St. Louis, MO. | Commercial Services |
ResistanceBio, Inc.
ResistanceBio, Inc. BiotechnologyHealth Technology ResistanceBio, Inc. is a company that focuses on overcoming treatment-resistant cancer. The company is based in San Carlos, CA. The company's mission is to defeat this type of cancer by developing a novel class of multi-targeted oncology treatments called Resistance Suppressing Therapy (REST). ResistanceBio was founded by Nicholas Goldner and Christopher Bulow, with Nicholas Goldner serving as the CEO since incorporation. | Health Technology |
